Human-derived and new synthetic injectable materials for soft-tissue augmentation: current status and role in cosmetic surgery.
The recent development of human-derived and new synthetic filling agents heralds a new era in soft-tissue augmentation. Many of the disadvantages of xenogenic and prior exogenous materials have been overcome with the advent of these autologous, allogeneic, and inert synthetic alternatives. Early reports using human-derived and inert exogenous filling agents have demonstrated good results and prolonged correction. It is too early, however, to assess the long-term efficacy of these agents. Future investigations should include histologic examination after facial implantation to document long-term safety and efficacy.
Alster
T S
TS
Washington Institute of Dermatologic Laser Surgery, DC, USA. talster@skinlaser.com
West
T B
TB
D001672:Biocompatible Materials; D003094:Collagen / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005145:Face; D005549:Foreign-Body Reaction / Q000517:prevention & control; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D007279:Injections, Subcutaneous; D019904:Polymethyl Methacrylate / Q000008:administration & dosage; D015595:Skin Aging; D015626:Tissue Expansion / Q000379:methods*; D014184:Transplantation, Homologous
D001672:Biocompatible Materials; D006820:Hyaluronic Acid; D003094:Collagen; D019904:Polymethyl Methacrylate